血清标志物在肝癌早期诊断中的研究进展  

Research progress of serum markers in early diagnosis of liver cancer

作　　者：王冰洁 张佳光[1] 杨婧 WANG Bing-jie;ZHANG Jia-guang;YANG Jing(Department of Infectious Disease,the Third Clinical Medical College of Three Gorges University,Gezhouba Central Hospital of Sinopharm,Yichang 443002,Hubei,CHINA)

机构地区：[1]三峡大学第三临床医学院国药葛洲坝中心医院感染性疾病科,湖北宜昌443002

出　　处：《海南医学》2020年第23期3101-3104,共4页Hainan Medical Journal

基　　金：2015-2016年度湖北省卫生计生西医类一般项目(编号:WJ2015MB183)。

摘　　要：目前临床上诊断肝癌多以病理组织学及影像学为主要依据,但只有在瘤体长到一定体积时才能诊断,此时肿瘤已大多进入晚期,患者预后差。血清甲胎蛋白(AFP)作为肝癌筛查的主要血清学指标,由于敏感性不高导致其诊断的准确性差强人意,因此临床上迫切需要寻找新的肝癌血清标志物。本文将针对近年来肝细胞癌血清学诊断进展做一综述。At present,clinical diagnosis of liver cancer is mostly based on histopathology and imaging,but it can only be diagnosed when the tumor grows to a certain volume,and the prognosis of patients with hepatocellular carcinoma(HCC)is generally poor because the tumors have entered advanced stage.The diagnostic accuracy of serum alpha fetoprotein(AFP),as the main indicators for liver cancer screening,is unsatisfactory and questionable because of low sensitivity,therefore there is a strong demand by clinicians for new HCC-specific biomarkers.This article will review the progress of serological diagnosis of HCC in recent years.

关 键 词：原发性肝细胞肝癌 甲胎蛋白阴性肝癌 流行病学 早期诊断 血清学标志物 诊断价值 

分 类 号：R735.7[医药卫生—肿瘤]